ADR-B2 – rs1042714 is a single nucleotide polymorphism (SNP) in the ADRB2 gene that results in a change in the amino acid sequence of the beta-2 adrenergic receptor (a G protein–coupled receptor). The variant is often referred to in studies of receptor function and population genetics because it is relatively common and alters receptor behavior at the protein level. The beta-2 adrenergic receptor mediates cellular responses to catecholamines (epinephrine and norepinephrine), influencing smooth muscle relaxation, vasodilation, cardiac chronotropy, and metabolic processes like lipolysis. rs1042714 variants have been identified in candidate-gene and population studies and are frequently evaluated for their associations with physiological response patterns and pharmacogenetic variability.

Genetic results for rs1042714 are reported as specific alleles or genotypes rather than numeric “levels.” Genotypes linked to relatively higher receptor signaling or reduced receptor downregulation may associate with stronger vasodilatory or metabolic responses to catecholamines. Conversely, genotypes associated with reduced signaling or increased receptor downregulation may correspond with blunted vascular or metabolic responsiveness. These patterns are associations, not diagnoses. Interpretation is most informative when combined with Cardio Zoomer’s vascular function, inflammation, lipid, and metabolic markers, because the clinical significance of the genotype depends on the overall biomarker and clinical context.

rs1042714 is included in Cardio Zoomer to provide inherited context for adrenergic signaling that influences vascular tone, metabolic responses, and potential medication response patterns. When integrated with blood and urine biomarkers, this variant helps clinicians separate inherited tendencies from acquired changes and supports more personalized interpretation of cardiovascular risk patterns.